rss
Ann Rheum Dis doi:10.1136/annrheumdis-2014-205278
  • Letter

Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody

  1. Chunde Bao2
  1. 1Department of Pneumology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
  2. 2Department of Rheumatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
  1. Correspondence to Professors Chunde Bao and Qiang Guo, Rhematology Department of Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, No.145, Shangdong (c) Road, 200001, Shanghai, China; baochunde_1678{at}126.com and marquisjerry{at}126.com
  • Received 23 January 2014
  • Revised 16 March 2014
  • Accepted 22 March 2014
  • Published Online First 16 April 2014

Clinical amyopathic dermatomyositis (CADM) is a special spectrum of dermatomyositis; there is prominent skin disease, but minimal or absent muscle disease.1 Rapidly progressive interstitial pneumonia (RPIP) in CADM has been reported predominantly in Asia. In contrast, Cottin et al2 reported a benign course of interstitial pneumonia in European patients with CADM. The treatment of CADM accompanied with RPIP is challenging, complicated by its rarity and heterogeneity. Generally, this condition is resistant to therapy and commonly fails to respond to aggressive therapy, such as high-dose corticosteroids and immunosuppressants and has a very poor outcome and prognosis.3–6 Interleukin 2 receptor α chain (IL-2Rα, or CD25), a high affinity receptor, is expressed on T and B lymphocytes after their activation. Little IL-2Rα is expressed on unstimulated lymphocytes or is found as soluble IL-2 receptor (sIL-2R) in the serum of healthy people, however, increases in sIL-2R are seen in the setting of autoimmune diseases.7 sIL-2R levels have …

Free sample This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of ARD.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article